In 2015, CureDuchenne supplied early funding to Capricor Therapeutics in support of a novel, first-in-class therapy to improve cardiac function in people with Duchenne muscular dystrophy. Duchenne can cause debilitating damage to the diaphragm, lungs and heart as the disease progresses. Cardiac treatments like CAP-1002 could significantly improve outlooks for everyone living with the disease, regardless of mutation.
During Phase I/II HOPE clinical trials, Capricor’s investigational cell therapy, CAP-1002, showed promising improvements in the heart and skeletal muscle of those in advanced stages of Duchenne. Today, in advance of Phase 3 clinical trial to support US FDA approval, NS Pharma and Capricor Therapeutics announced an agreement to commercialize and distribute CAP-1002.
CureDuchenne is pleased to share details on this exciting development through NS Pharma’s letter to the community: